Aktiesnakken — August 2012
-
Novo Nordisk today announced that insulin degludec has passed the review by the First Committee on Drugs of Japan's Pharmaceutical Affairs. The remaining step in the regulatory process will now be an official approval from the Ministry of Health, Labour and Welfare (MHLW).
-
well, det er da et skridt fremad og ikke tilbage
-
tja ved heller ikke. men generelt går novo aktien da meget godt
-
fra 780 til 933 på 3 måneder
-
FB i 18,04.....
-
not bad
hvornår var den i 340? -
spændende hvornår den rammer bunden
men ikke lige på den nyhed tror jegHello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind